Gengo Peter J, Pettit Hugh O, O'Neill Scott J, Su Ying Fu, McNutt Robert, Chang Kwen-Jen
Ardent Pharmaceuticals, Inc., 631 United Dr., Suite 200, Durham, NC 27713, USA.
J Pharmacol Exp Ther. 2003 Dec;307(3):1227-33. doi: 10.1124/jpet.103.054429. Epub 2003 Oct 8.
Allyl-2,5-dimethyl-1-piperazines have been of interest as analgesic agents for the management of moderate-to-severe pain. In this study, we compared the antinociceptive properties and respiratory depressant activity of one such agent, (+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide (DPI-3290), with those of established narcotic analgesics, morphine and fentanyl. Intravenous administration of DPI-3290 in conscious laboratory rats increased antinociception in a dose-dependent manner with a corresponding ED(50) value of 0.05 +/- 0.0072 mg/kg. Simultaneous measurement of arterial blood gas in animals treated with DPI-3290 demonstrated dose-dependent increases in pCO2 with an ED(50) value of 0.91 +/- 0.22 mg/kg. In comparison, morphine and fentanyl increased antinociception in rats with ED(50) values of 2.01 +/- 0.0005 and 0.0034 +/- 0.00024 mg/kg, respectively, and the ED(50) value for morphine-induced changes in pCO2 was 4.23 +/- 0.72 mg/kg, whereas the ED(50) value for fentanyl-induced changes in pCO2 was 0.0127 +/- 0.0035 mg/kg. A separate series of experiments were designed to examine the effects of DPI-3290 on mu-opioid receptor induced antinociception and hypercapnia. Intravenous bolus doses of DPI-3290 that ranged from 0.2 to 1.0 mg/kg had no effect on antinociception mediated by alfentanil (2 microg/kg/min i.v.) but reduced hypercapnia by approximately 50%. Results from these studies demonstrate the equivalent antinociceptive efficacy of DPI-3290, morphine, and fentanyl but dramatic differences in the hypercapnia that antinociceptive doses of these drugs produce. When measured simultaneously, DPI-3290 had an 18.2-fold difference in the ratio comparing the ED(50) value for antinociception with the ED(50) value for changes in pCO2; this ratio was 2.1 for morphine and 3.7 for fentanyl. Furthermore, DPI-3290 reduced the alfentanil-mediated hypercapnia without any effect on antinociception. Together, the balanced opioid agonist activity of DPI-3290 may provide a means of powerful analgesia while mitigating the mu-opioid receptor-mediated hypercapnia.
烯丙基 - 2,5 - 二甲基 - 1 - 哌嗪类化合物作为治疗中重度疼痛的镇痛剂受到关注。在本研究中,我们比较了一种此类药物(+)-3 - ((α - R)-α - ((2S,5R)-4 - 烯丙基 - 2,5 - 二甲基 - 1 - 哌嗪基)-3 - 羟基苄基)-N - (3 - 氟苯基)-N - 甲基苯甲酰胺(DPI - 3290)与已有的麻醉性镇痛药吗啡和芬太尼的抗伤害感受特性及呼吸抑制活性。在清醒的实验大鼠中静脉注射DPI - 3290,其抗伤害感受作用呈剂量依赖性增加,相应的半数有效剂量(ED50)值为0.05±0.0072mg/kg。对接受DPI - 3290治疗的动物同时测量动脉血气,结果显示pCO2呈剂量依赖性增加,ED50值为0.91±0.22mg/kg。相比之下,吗啡和芬太尼使大鼠抗伤害感受增加,其ED50值分别为2.01±0.0005和0.0034±0.00024mg/kg,吗啡诱导pCO2变化的ED50值为4.23±0.72mg/kg,而芬太尼诱导pCO2变化的ED50值为0.0127±0.0035mg/kg。设计了另一系列实验来研究DPI - 3290对μ - 阿片受体诱导的抗伤害感受和高碳酸血症的影响。静脉推注剂量范围为0.2至1.0mg/kg的DPI - 3290对阿芬太尼(2μg/kg/min静脉注射)介导的抗伤害感受无影响,但可使高碳酸血症降低约50%。这些研究结果表明DPI - 3290、吗啡和芬太尼具有同等的抗伤害感受效力,但这些药物的抗伤害感受剂量所产生的高碳酸血症存在显著差异。同时测量时,DPI - 3290在比较抗伤害感受的ED50值与pCO2变化的ED50值的比值上有18.2倍的差异;吗啡的该比值为2.1,芬太尼为3.7。此外,DPI - 3290可降低阿芬太尼介导的高碳酸血症,而对抗伤害感受无任何影响。总之,DPI - 3290的平衡阿片类激动剂活性可能提供一种强效镇痛的方法,同时减轻μ - 阿片受体介导的高碳酸血症。